Hepatic glycogen storage disorders: what have we learned in recent years? by Burda, Patricie & Hochuli, Michel
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Hepatic glycogen storage disorders: what have we learned in recent years?
Burda, Patricie; Hochuli, Michel
Abstract: PURPOSE OF REVIEW Glycogen storage disorders (GSDs) are inborn errors of metabolism
with abnormal storage or utilization of glycogen. The present review focuses on recent advances in hep-
atic GSD types I, III and VI/IX, with emphasis on clinical aspects and treatment. RECENT FINDINGS
Evidence accumulates that poor metabolic control is a risk factor for the development of long-term com-
plications, such as liver adenomas, low bone density/osteoporosis, and kidney disease in GSD I. However,
mechanisms leading to these complications remain poorly understood and are being investigated. Molec-
ular causes underlying neutropenia and neutrophil dysfunction in GSD I have been elucidated. Case
series provide new insights into the natural course and outcome of GSD types VI and IX. For GSD III,
a high protein/fat diet has been reported to improve (cardio)myopathy, but the beneficial effect of this
dietary concept on muscle and liver disease manifestations needs to be further established in prospective
studies. SUMMARY Although further knowledge has been gained regarding pathophysiology, disease
course, treatment, and complications of hepatic GSDs, more controlled prospective studies are needed to
assess effects of different dietary and medical treatment options on long-term outcome and quality of life.
DOI: 10.1097/MCO.0000000000000181
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-117633
Published Version
Originally published at:
Burda, Patricie; Hochuli, Michel (2015). Hepatic glycogen storage disorders: what have we learned
in recent years? Current Opinion in Clinical Nutrition and Metabolic Care, 18(4):415-421. DOI:
10.1097/MCO.0000000000000181
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
 CURRENTOPINION Hepatic glycogen storage disorders: what have we
learned in recent years?
Patricie Burdaa,c and Michel Hochulib,c
Purpose of review
Glycogen storage disorders (GSDs) are inborn errors of metabolism with abnormal storage or utilization
of glycogen. The present review focuses on recent advances in hepatic GSD types I, III and VI/IX, with
emphasis on clinical aspects and treatment.
Recent findings
Evidence accumulates that poor metabolic control is a risk factor for the development of long-term
complications, such as liver adenomas, low bone density/osteoporosis, and kidney disease in GSD I.
However, mechanisms leading to these complications remain poorly understood and are being investigated.
Molecular causes underlying neutropenia and neutrophil dysfunction in GSD I have been elucidated. Case
series provide new insights into the natural course and outcome of GSD types VI and IX. For GSD III, a high
protein/fat diet has been reported to improve (cardio)myopathy, but the beneficial effect of this dietary
concept on muscle and liver disease manifestations needs to be further established in prospective studies.
Summary
Although further knowledge has been gained regarding pathophysiology, disease course, treatment, and
complications of hepatic GSDs, more controlled prospective studies are needed to assess effects of different
dietary and medical treatment options on long-term outcome and quality of life.
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INTRODUCTION
Glycogen is the storage form of glucose in mamma-
lian cells and is most abundant in liver and muscle.
In liver, glycogen serves as a source of glucose to
maintain normal blood glucose between meals. In
muscle, glycogen provides glucose for glycolysis and
ATP production, the energy for active contracting
muscle cells. Glycogen storage disorders (GSDs) are a
group of inborn errors ofmetabolismwith abnormal
storage or utilization of glycogen, resulting from
various genetic deficiencies of enzymes for glycogen
breakdown or synthesis, or from mutations of
proteins regulating glycogen metabolism. Different
types of GSDs are classified on the basis of the
deficient enzymes and affected tissues [1]. Hypogly-
cemia and hepatomegaly are the cardinal presenting
features of GSDs affecting the liver. Exercise intol-
erance with muscle pain and rhabdomyolysis, or
muscle weakness and cardiomyopathy are signs of
GSDs affecting muscles. Long-term complications
are frequent with GSDs, often constituting the main
disease burden over time.
In recent years, additional knowledge has been
gained about the pathophysiology, disease course,
treatment, and complications associated with GSDs.
The present review focuses on advances in hepatic
GSD types I, III, and VI/IX (Table 1), with emphasis
on clinical aspects relevant for treatment and
follow-up of patients.
GLYCOGEN STORAGE DISEASE TYPE I
GSD type I (GSD I) occurs in two subtypes resulting
fromdeficiencies of glucose-6-phosphatase (G6Pase-a)
or the glucose-6-phosphate transporter (G6PT).
G6PT translocates G6P into the endoplasmic
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reticulum, wherein the phosphatase reaction cata-
lyzed by G6Pase-a takes place [1,2
&&
]. The subtype
GSD Ia (G6Pase-a deficiency) is most prevalent.
About 20% of GSD I patients are classified as GSD
Ib (G6PT deficiency) [2
&&
]. The primary metabolic
abnormality of both subtypes of GSD I is fasting
hypoglycemia, because glucose cannot be formed
from glucose-6-phosphate that is produced either
via gluconeogenesis or glycogenolysis (Fig. 1). Other
associated metabolic abnormalities are lactic acido-
sis, marked hypertriglyceridemia, hypercholestero-
lemia, and hyperuricemia, depending on metabolic
control [1].
Dietary treatment is the cornerstone of GSD I
therapy. A regular carbohydrate intake is necessary
to avoid hypoglycemia and to achieve good meta-
bolic control. Glucose requirements generally
decrease with age, and adults typically have a longer
fasting tolerance. Traditional approaches to main-
tain normoglycemia during night-time are continu-
ous tube feeding, or ingestion of slowly digested
carbohydrates at bedtime, usually uncooked corn
starch (UCCS). A modified form of corn starch (Gly-
cosade) with a different content of amylopectin
and resistant starch can prolong euglycemia over-
night in some patients [3]. A systematic review and
metaanalysis of different dietary approaches to
maintain normoglycemia in GSD I has shown that
both (intermittent) UCCS and continuous feeding
of dextrose safely maintain normal blood glucose
during nighttime, and physical development was
similar for both treatment options [4
&
]. During
daytime, intermittent administration of UCCS pre-
vented hypoglycemia in children more effectively
than intermittent dextrose alone or an UCCS–
dextrose mixture. However, conclusions of this
meta-analysis were based on four relatively small
trials, with limitations such as the heterogeneity in
duration of treatment and follow-up, patient age,
and disease severity, as well as lack of information
on additional dietary factors [5]. In practice, large
intraindividual and interindividual differences in
glucose response to diet are common, although
only small differences in digestibility were observed
between different brands of UCCS and modified
corn starch in a standardized in-vitro gastrointesti-
nal model [6]. However, many additional factors
will influence the kinetics of glucose release in vivo.
The optimal mode to deliver carbohydrates remains
to be tailored to the individual patient, with the goal
to achieve best possible metabolic control. Special
care has to be taken to avoid excessive energy intake
and ensure a balanced diet with adequate macro-
nutrient and micronutrient intake [7].
Despite optimal treatment, many GSD I patients
will develop complications such as liver adenomas,
chronic kidney disease, urolithiasis, low bone
density/osteoporosis, and anemia. Neutropenia
and inflammatory bowel disease (IBD) are charac-
teristic features of GSD Ib (Table 1) [8]. Recently,
guidelines regarding diagnosis and management of
GSD I have been released [9
&&
].
Development of liver adenomas is frequent, with
a risk of rupture and bleeding, local compression,
and progression into malignancy (hepatocellular
carcinoma). Evidence is accumulating that poor
metabolic control may be a risk factor for adenoma
formation. High triglyceride levels adversely affected
adenoma-free survival [10]. In line with this obser-
vation, regression of adenoma size was documented
in some patients once better metabolic control with
lower triglycerides was achieved [11].
However, liver adenomas can also develop in
patients with good and stable metabolic control,
and the biology of adenoma formation in GSD I
still is incompletely understood. Commonly, hep-
atic adenomas are classified into four molecular
subtypes. Molecular characterization of resected
adenomas revealed a distinct profile of molecular
subtypes in GSD I compared with sporadic adeno-
mas [12
&&
], with a higher proportion of adenomas
activated for b-catenin (CTBNN1 mutation), a sub-
type associated with a higher risk of malignant
transformation. To date, no specific imaging pro-
cedure or biochemical test can reliably exclude
malignant transformation of liver adenomas, often
resulting in management dilemmas in case of size
progression of liver adenomas. Specific circulating
micro-RNAs in plasma may constitute a new
approach to monitor adenoma formation in the
future, although the additional value of micro-RNAs
to discriminate benign adenomas from areas of
malignant transformation will need to be demon-
strated [13].
KEY POINTS
 GSDs are multisystemic disorders and have to be
managed in a cross-disciplinary way.
 Poor metabolic control is a risk factor for the
development of long-term complications.
 Hepatic complications such as liver fibrosis/cirrhosis
can also occur in GSD IX subtypes previously
considered as benign.
 A high protein/fat diet reduced in carbohydrates has
been reported to improve (cardio)myopathy in GSD III.
 More prospective studies are needed to assess the
effects of different dietary and medical treatment
options on long-term outcome and quality of life.
Carbohydrates
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Anemia is highly prevalent in GSD I, and the
degree of anemia strongly correlates with the pres-
ence of liver adenomas especially in GSD I [14].
Hepcidin production by liver adenomas is likely
to contribute to iron refractory anemia due to
reduction of intestinal absorption and recycling of
iron by macrophages. However, an anemia of
chronic disease is often observed without the pres-
ence of liver adenomas, although often less severe.
Adenoma resection may improve anemia in many
patients. In GSD Ib, anemia is also associated with
the presence and severity of IBD [14]. Recently, a
case series demonstrated that IBD rarely can also be
present in patients with GSD Ia [15]. Progressive
anemia should prompt an evaluation for the pres-
ence of IBD or liver adenomas.
Molecular mechanisms leading to neutropenia
and neutrophil dysfunction in GSD Ib are being
elucidated [2
&&
]. Deficiency of the G6PT/G6Pase-b
complex in neutrophils impairs energy homeostasis
and function, and activates the hypoxia-inducible
factor-1a/peroxisome proliferator-activated recep-
tor-g pathway leading to impairments in respiratory
burst, chemotaxis, and calcium mobilization [16
&&
].
Disturbed bone metabolism with low bone
density is a typical feature of GSD I. Recent studies
confirmed that low bone density is associated with
poorer metabolic control (higher triglycerides and
higher blood lactate), poor treatment compliance,
and the presence of other long-term complications
[17,18
&
]. In GSD Ib, reduced bone density correlates
with granulocyte colony-stimulating factor (G-CSF)
treatment, more specifically the duration of treat-
ment and lower age at initiation of G-CSF treatment
[18
&
].
Chronic kidney disease is frequent with micro-
albuminuria as a first sign of glomerular damage.
GSD nephropathy can evolve to overt proteinuria
and/or renal failure especially in the setting of poor
metabolic control. Kidney disease in GSD I is similar
to diabetic nephropathy, although the pathogenesis
is still unclear. A mouse model with a targeted
Table 1. Overview of hepatic GSDs presented in this review
GSD type
Presentationa Typical associated complicationsEnzyme affected/gene
GSD I (Van Gierke) Hepatic GSD Ia and Ib:
Ia: Glc-6-phosphatase a (G6PC) Liver adenomas – hepatocellular carcinoma
Ib: Glc-6-phosphate transporter
(G6PT, SLC37A4)
Chronic kidney disease with renal failure
Osteopenia–Osteoporosis
Nephrolithiasis
Gout
Anemia, platelet dysfunction
GSD Ib:
Neutropenia, impaired neutrophil function
Inflammatory bowel disease
GSD IIIa/b (Cori, Forbes)
Debranching enzyme/AGL
GSD IIIab: Liver fibrosis – Cirrhosis – Liver failure
Hepatic and myopathic Liver adenomas – Hepatocellular carcinoma
GSD IIIb: Hepatic Progressive myopathy
Concentric hypertrophic cardiomyopathy
Cardiac dysfunction–Arrhythmias
GSD VI Hepatic (generally mild)c See type IX, adults often asymptomatic
Glycogen Phosphorylase/PYGL
GSD IX Hepatic (very variable,
often mild)
Clinical and biochemical features often improve with age
IXa (X-linked liver glycogenosis; XLG) Liver fibrosis–Cirrhosis (mostly IXc, PHKG2)
Phosphorylase b kinase/a-subunit (PHKA2)
IXb Phosphorylase b kinase/b-subunit (PHKB)d
IXc Phosphorylase b kinase/g-subunit (PHKG2)
GSD, Glycogen storage disorder. With the exception of GSD IXa (X-linked inheritance) all GSDs listed are inherited in a autosomal recessive manner.
aCardinal symptoms of a hepatic presentation: hypoglycemia and hepatomegaly. Cardinal symptoms of a myopathic presentation: progressive muscle weakness
and/or cardiomyopathy.
bHepatic symptoms usually predominant in children, myopathy with increasing age.
cCardiomyopathy has been observed in some cases with GSD VI.
dSome degree of (cardio)myopathy may be observed with IXb.
Hepatic glycogen storage disorders Burda and Hochuli
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deletion of kidney G6Pase has been generated and
will enable further research to decipher molecular
mechanisms underlying renal failure in GSD I [19
&
].
Growth retardation with short stature, and/or
delayed puberty is often associated with GSD I.
Multiple factors may contribute to these problems,
butunderlyingmechanismsare incompletelyunder-
stood. Despite the frequent occurrence of irregular
menses, fertility seems intact with successful preg-
nancies and good neonatal outcome [20]. There is
evidence for hepatic growth hormone resistance in a
mouse model [21
&
], but the pathophysiology of the
typical growth retardation in humans remains to be
further investigated.
Quality of life can be impaired in adult patients
with GSD I. According to a recent study using the
standardized Short Form (36) Health Survey (SF-36)
questionnaire, especially patients with GSD type
Ib, women, and those with renal complications were
more likely to have an impaired quality of life [22
&
].
Optimal management and prevention of long-
term complications in GSD I remains difficult. Liver
transplantation is a therapeutic option for patients
with recurrent progressive adenomatosis not ame-
nable to liver resection, or when hepatocellular
carcinoma is suspected. Liver transplantation cor-
rects the metabolic abnormality and glucose
homeostasis, in exchange with the risk of the pro-
cedure and the morbidity of lifelong immuno-
suppression [23
&&
]. Some long-term problems
persist after transplantation, such as chronic kidney
disease, and in GSD Ib neutropenia/neutrophil dys-
function and IBD.
Experimental therapies such as delivering
deficient G6Pase activity to the liver by gene therapy
are being investigated in animal models [24
&
,25].
The gradual loss of transgene expression remains
a significant challenge in the development of such
therapies. Liver stem cell therapy also is being
studied as a future therapeutic option [26].
GLYCOGEN STORAGE DISEASE TYPE III
GSD type III (GSD III) is caused by a deficiency of
glycogen debrancher enzyme (amylo-1,6-glucosi-
dase) and results in accumulation of ‘abnormal’
glycogen with short outer chains in various tissues
(Table 1) [1,27]. There are two major GSD III sub-
types: GSD type IIIa affects both the liver and
muscle and accounts for approximately 80% of all
GSD III cases, whereas patients with GSD IIIb only
have symptoms of liver disease. Great phenotypic
diversity is observed with variable severity of the
clinical course.
During infancy and early childhood, the hepatic
presentation is predominant with hepatomegaly,
hypoglycemia, elevated transaminases, and hyper-
lipidemia. These features often improve with age;
however, long-term complications can develop in
a significant proportion of patients such as liver
fibrosis/cirrhosis with a risk of hepatic carcinoma
formation, or rarely hepatic adenomas. Clinically
relevant myopathy with slowly progressive muscle
weakness typically develops later and may become
a predominant feature in adults with GSD IIIa.
Exercise tests showed that skeletalmuscle symptoms
not only are caused by muscle wasting, but may
also be related to insufficient energy production due
to reduced glycogenolytic capacity [28
&
]. Cardio-
myopathy can also develop and usually presents
with asymptomatic left ventricular hypertrophy,
but can progress to hypertrophic cardiomyopathy
with decreased left ventricular function and/or
arrhythmias [29].
Generally, cognitive impairments have not
been associated with GSD III. Recently, cognitive,
Glycogen
Glucose-6-PGlucose
Glycolysis
Glycogeno-
lysis
Fatty acids
Triglycerides
TCA
cycle
Gluconeo-
genesis
Pentose-P
pathway
Uric acid
Pyruvate
Acetyl-
CoA
Lactic acid
Glycogenesis
GSD I
GSD VI / GSD IX
GSD III
FIGURE 1. Metabolic derangements in liver glycogenoses
(glycogen storage disorders). During fasting the liver
maintains glucose homeostasis through glycogen breakdown
(glycogenolysis) and gluconeogenesis. Dephosphorylation of
Glc-6-P to glucose catalyzed by Glc-6-phosphatase is the last
step of glucose formation. In glycogen storage disorders
type 1 (GSD I) dysfunction of this last step results in
hypoglycemia when exogenous carbohydrates are
exhausted. Accumulation of Glc-6-P with increased fluxes
through the glycolytic and lipogenic pathways is one of the
proposed mechanisms for hyperlactatemia and
hypertriglyceridemia. In GSD types III, VI and IX, glucose
production via glycogenolysis is impaired but
gluconeogenesis is functional. () denotes metabolic
abnormalities specifically related to GSD I.
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psychopathological, and behavioral profiles were
characterized in a small cohort of GSD III patients
[30], revealing some psychological and attention
deficits. However, a causative role of the metabolic
derangement has not been demonstrated.
GSD III management guidelines were published
a few years ago [27]. Dietary treatment is the main-
stay of therapy. Prevention of hypoglycemia and
maintenance of euglycemia is the main focus in
early childhood. Hypoglycemia is controlled by fre-
quent carbohydrate meals and a form of continuous
carbohydrate supply overnight (e.g., UCCS) [27].
In contrast to GSD I, protein can be used as an
additional source for glucose production because
gluconeogenesis is functional. In recent years,
several reports have been published showing an
improvement of (cardio)myopathy following a high
protein or protein/fat diet reduced in carbohydrates
[31,32
&
,33,34]. Such findings highlight the import-
ance of protein in the dietary treatment of GSD III.
Sufficient amounts of protein replacing dietary
carbohydrates may reduce the accumulation of
‘abnormal’ short-branched glycogen in affected
organs. Whether long-term muscular, cardiac, or
even liver complications can be prevented by this
dietary approach cannot be answered at present and
needs to be further investigated with systematic
prospective studies over a longer period [35
&&
].
GLYCOGEN STORAGE DISEASE VI/IX
Glycogen phosphorylase kinase catalyzes the phos-
phorylation of inactive glycogen phosphorylase
converting the phosphorylase to its active form.
Subsequently, phosphorylase catalyzes the sequen-
tial cleavage of glucosyl units from glycogen to
release glucose 1-phosphate. GSD type VI is caused
by glycogen phosphorylase deficiency. GSD type IX
results from dysfunctional phosphorylase kinase, an
enzyme consisting of four subunits. Different GSD
IX subtypes are described, depending on the subunit
affected [1,36
&&
]. The clinical presentation is very
heterogeneous and variable, classically mild with
hepatomegaly, elevated transaminases and dys-
lipidemia, but can also be more severe with short
stature, hypoglycemia, and progressive liver disease/
cirrhosis (Table 1). Childhood symptoms often
improve with age. Mild cardiomyopathy has been
observed in GSD VI and GSD IXb [36
&&
]. The most
commonGSD IX subtype is IXa, due tomutations in
the a-subunit of phosphorylase kinase, encoded by
the PHKA2 gene. GSD IXa is likely to be an under-
diagnosed cause of ketotic hypoglycemia [37]. The
clinical picture of GSD IXa virtually overlaps with
GSD type VI, except that inheritance of GSD type
IXa is X-linked, whereas GSD VI is an autosomal
recessive disorder. Therefore, GSD type VI and IXa
mainly are differentiated by molecular genetic
investigations. GSD IXc related to mutations in
the g-subunit (PHKG2) is associated with a more
severe phenotype and a high prevalence of liver
fibrosis that can even present with cirrhosis in child-
hood [38]. The g-subunit contains the catalytic site
of the enzyme that might explain the more severe
phenotype. In contrast, GSD IXa classically has been
regarded as a benign condition without compli-
cations, and treatment has often been considered
unnecessary. But case reports are emerging that liver
fibrosis/cirrhosis can also develop with GSD IXa
[36
&&
,39
&
]. In a case series, it was shown that aggres-
sive structured dietary treatment with UCCS and a
relatively high protein intake not only resulted in
improvement of growth velocity, general well-being
and energy, hepatomegaly and biochemical abnor-
malities, but also regression of sonographic features
of fibrosis [39
&
].
DIAGNOSIS OF HEPATIC GLYCOGEN
STORAGE DISEASES
In the first instance, the diagnosis of hepatic GSDs
requires a careful clinical history and examination.
Typical laboratory abnormalities help to differen-
tiate between the GSD types (Table 1). Biotinidase
activity has been presented as a useful biomarker for
hepatic GSDs [40,41]. The definite diagnosis finally
is a combination of clinical presentation, specific
constellation of biochemical abnormalities, deter-
mination of liver enzyme activity (if necessary), and
molecular genetic analysis. With the advances in
next-generation sequencing (NGS) technologies,
mutation analysis has become a preferred method
for diagnosing GSDs [42
&
]. The NGS approach is
attractive, because a group of candidate genes can
be sequenced simultaneously and liver biopsies
requiring very careful specimen handling can be
avoided. Nevertheless, the detection rate of GSDs
is highly dependent on an accurate clinical and
laboratory evaluation and novel mutations can be
only confirmed as disease causing by measuring the
according enzyme activity.
CONCLUSION
A cross-disciplinary approach including intensive
dietary treatment to achieve good metabolic con-
trol, and adequate medical (or surgical) therapy of
associated problems and complications is essential
to reduce morbidity, mortality, and improve the
quality of life of patients with GSDs. However,
despite optimal treatment and compliance, long-
term complications often develop and mechanisms
Hepatic glycogen storage disorders Burda and Hochuli
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remain poorly understood. Controlled prospective
clinical trials to evaluate treatment options are
scarce, which is a general problem in the field of
rare diseases. Recommendations often are based on
clinical experience and expert opinion. Prospective
studies are needed to assess effects of different
dietary andmedical treatment options on long-term
outcome and quality of life. In future, proteomic
and metabolomic techniques might identify new
biomarkers useful for patient follow-up and moni-
toring of treatment efficacy.
New experimental treatment approaches, such
as hepatic gene therapy or liver stem cell therapy are
being investigated in animal models. However, risks
and additional benefits over established treatment
options in humans remain to be studied.
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